Immune checkpoint inhibitors (ICIs) using antibodies against programmed cell death 1 (PD-1) or programmed death ligand 1 (PD-L1) had achieved great success in cancer treatment, meanwhile not all patients responded to the ICIs immunotherapy (Xu et al. 2022). The gene discussed is PDCD1; the disease is cancer.